Mangoceuticals, Inc.
MGRX
$2.49
-$0.08-3.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.14% | -18.26% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.14% | -18.26% | |||
| Cost of Revenue | -50.49% | -45.72% | |||
| Gross Profit | -3.14% | 18.48% | |||
| SG&A Expenses | 9.86% | -19.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 52.08% | -28.60% | |||
| Operating Income | -58.57% | 29.39% | |||
| Income Before Tax | 2.56% | 16.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.56% | 16.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -60.00% | 66.67% | |||
| Net Income | 2.54% | 16.39% | |||
| EBIT | -58.57% | 29.39% | |||
| EBITDA | -10.57% | 29.29% | |||
| EPS Basic | -8.42% | 27.76% | |||
| Normalized Basic EPS | 25.11% | 27.76% | |||
| EPS Diluted | -8.42% | 27.76% | |||
| Normalized Diluted EPS | 25.11% | 27.76% | |||
| Average Basic Shares Outstanding | 30.14% | 15.74% | |||
| Average Diluted Shares Outstanding | 30.14% | 15.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||